Last updated: February 20, 2026
What Is NDC 70000-0204?
The drug with NDC 70000-0204 is Stelara (ustekinumab), a monoclonal antibody that targets interleukin-12 and interleukin-23 pathways. It is primarily used to treat psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis. The drug is marketed by Johnson & Johnson.
Market Landscape
Competitive Position
Stelara faces competition from biologics including Humira (adalimumab), Cosentyx (secukinumab), and Tremfya (guselkumab). As of 2022, it maintains a significant share in moderate to severe plaque psoriasis and Crohn’s disease markets.
Market Size and Demand
Psoriasis Market
- Estimated global psoriasis market value: USD 12 billion in 2022.
- Stelara’s market share: Approximately 25-30%, translating into USD 3-3.6 billion.
Crohn’s Disease Market
- Estimated global Crohn’s disease market: USD 6 billion.
- Stelara's share: About 20%, roughly USD 1.2 billion.
Trends Influencing Market
- Increasing prevalence: Psoriasis affects 2-3% of the global population.
- Physician adoption: Growing preference for biologics over traditional systemic therapies.
- Originator renewal: Patent cliffs threaten to reduce prices; biosimilar entries expected post-expiry.
Patent Life and Exclusivity
- Patent expiration in the U.S.: 2023-2024 for key formulations.
- Data exclusivity in the U.S.: 12 years post-approval, through 2024 for U.S. patents.
- Biosimilar entry: Expected within 1-2 years of patent expiry, subject to FDA approval.
Pricing Analysis
Current Pricing Benchmarks
| Region |
Per-Patient Yearly Cost |
Notes |
| U.S. |
USD 65,000–USD 80,000 |
List price varies by indication and dosage |
| EU |
EUR 40,000–EUR 50,000 |
Slightly lower than U.S. |
| Canada |
CAD 80,000–CAD 90,000 |
Similar to U.S. prices |
Price Trends
- Before Patent Expiry: List prices remain stable, with discounts negotiated by payers.
- Post-Patent Expiry: Significant price reductions expected, ranging from 20-50%, as biosimilars enter.
Biosimilar Impact
- Biosimilars anticipated in 2024-2025.
- Expected price reductions: Up to 40% compared to originator prices.
- Market penetration: Targeted at 50-70% within 3 years of biosimilar launch.
Price Projections (2023-2027)
2023
- Patent expiry prompts initial drop.
- List prices: USD 65,000–USD 80,000.
- Biosimilar prices: USD 35,000–USD 50,000.
2024
- Biosimilar approvals expected.
- Market share of biosimilars: 10-20%.
- Average prices: The originator could reduce prices by 20%, leading to USD 52,000–USD 64,000 per patient annually.
2025–2027
- Increased biosimilar market share: 50–70%.
- Average prices decline to USD 30,000–USD 45,000.
- Total market size may shrink by 30–50%, depending on biosimilar adoption.
Revenue Forecasts
| Year |
Estimated Revenue (USD Billion) |
Assumptions |
| 2023 |
USD 3.5–4.0 |
Patents active, premium pricing. Biosimilar presence minimal. |
| 2024 |
USD 2.8–3.2 |
Biosimilars launch, market share begins shift. |
| 2025 |
USD 2.0–2.4 |
Biosimilar market share factors in, price reductions deepen. |
| 2026 |
USD 1.5–1.8 |
Biosimilar saturation increasing; originator’s market share declines. |
| 2027 |
USD 1.2–1.5 |
Biosimilar dominance, further price erosion. |
Strategic Implications
- Johnson & Johnson must prepare for biosimilar competition, including potential price cuts.
- Launching combination therapies or expanding indications may offset revenue declines.
- Early engagement with healthcare providers and payers remains critical.
Key Takeaways
- NDC 70000-0204 (Stelara) commands high prices, with USD 65,000–USD 80,000 annually in the U.S.
- Patent expiry and biosimilar entry expected in 2023–2024 will cause price reductions.
- Biosimilars could reduce originator revenues by 30–50%, with price cuts of up to 40%.
- Market dynamics will depend largely on biosimilar approval timelines, payer policies, and physician adoption rates.
- Strategic initiatives include expanding indications and optimizing biosimilar strategies.
FAQs
1. When do biosimilars for Stelara typically enter the market?
Biosimilars are expected to enter in 2024–2025, following patent expiries in 2023–2024.
2. What is the primary driver for price reductions?
Biosimilar competition will be the main factor, likely resulting in discounts of 20–50% from current list prices.
3. How will biosimilar adoption affect revenue?
Deployment of biosimilars could halve or more than halve current revenues within 3–4 years post-launch.
4. Are there new indications that could sustain revenue?
Yes. Expanding indications, such as applications in hidradenitis suppurativa or other autoimmune diseases, could help sustain sales.
5. What competitive strategies should Johnson & Johnson pursue?
Continuing innovation, strategic biosimilar partnerships, and expanding into new complementary indications improve market positioning amid biosimilar competition.
References
[1] IQVIA (2022). Global Dermatology Market Report.
[2] Eurostat (2022). Europe Psoriasis Market Data.
[3] FDA (2022). Biosimilar Approval Timeline.
[4] Johnson & Johnson Annual Report (2022).
[5] MarketWatch (2023). Biologic Drugs Price Trends.
